Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

0.4800 +0.0722 (+17.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Century Therapeutics to Present at the AACR Annual Meeting 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
From Century Therapeutics, Inc.
Via GlobeNewswire
8 Analysts Have This to Say About Century Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022
Via Benzinga
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 29 stocks made new 52-week lows. 
Via Benzinga
5 Health Care Stocks That Are Diving - And May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 13 stocks hit new 52-week lows. 
Via Benzinga
Top 5 Health Care Stocks That May Surge
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest. 
Via InvestorPlace
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
Via Benzinga
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
Via Benzinga
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
From Century Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
Century Therapeutics to Present at the SITC 37th Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
From Century Therapeutics, Inc.
Via GlobeNewswire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Announced Clearance To Century Therapeutics' Allogeneic Cell Therapy Candidate Study
Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or... 
Via Benzinga
U.S. Stock Futures Higher Following Friday's Rally
Pre-open movers 
Via Benzinga
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.